← Leaderboards
Da Yang
University Of Pittsburgh At Pittsburgh
$5,984,718
Attributed
$5,984,718
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,984,718 · 4
By mechanism
R01$5,984,718 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Timothy A Allen$915,730
- Yi Huang$1,791,828
- Carlos Cruchaga$41,433,350
- Steve A Kay$26,702,111
- Jeremy N Rich$24,023,429
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingIn VivoOverexpressionKnock-DownTumorIn VitroImmunoprecipitationGenesResistanceProteinsUntranslated RnaNucleotidesSamplingPlayTechnologyGene ExpressionPromoterRna BindingChip-SeqMalignant Breast NeoplasmLuciferasesGenetic TranscriptionReporter GenesBreast Cancer Cell
Grant awards (16)
Enhancer RNAs Boost MYC-Chromatin Interaction to Regulate Gene Expression and Tumorigenesis$408,907
R01 · FY2025 · CA · contact PI
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer$378,023
R01 · FY2025 · CA · contact PI
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition$376,250
R01 · FY2025 · CA · contact PI
Enhancer RNAs Boost MYC-Chromatin Interaction to Regulate Gene Expression and Tumorigenesis$399,745
R01 · FY2024 · CA · contact PI
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer$365,009
R01 · FY2024 · CA · contact PI
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition$357,438
R01 · FY2024 · CA · contact PI
Enhancer RNAs Boost MYC-Chromatin Interaction to Regulate Gene Expression and Tumorigenesis$433,981
R01 · FY2023 · CA · contact PI
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer$406,248
R01 · FY2023 · CA · contact PI
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition$368,725
R01 · FY2023 · CA · contact PI
The oncogenic role of EPIC1MYC axis in breast cancer$357,994
R01 · FY2022 · CA · contact PI
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition$353,169
R01 · FY2022 · CA · contact PI
The oncogenic role of EPIC1MYC axis in breast cancer$357,994
R01 · FY2021 · CA · contact PI
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition$357,994
R01 · FY2021 · CA · contact PI
The oncogenic role of EPIC1MYC axis in breast cancer$357,994
R01 · FY2020 · CA · contact PI
The oncogenic role of EPIC1MYC axis in breast cancer$347,253
R01 · FY2019 · CA · contact PI
The oncogenic role of EPIC1MYC axis in breast cancer$357,994
R01 · FY2018 · CA · contact PI